J&J reports positive Phase 3 data for Tecvayli in earlier blood cancer setting

Johnson & Johnson’s Tecvayli has achieved survival outcomes in a Phase 3 trial that bode well for its ambitions to expand its use to earlier lines of multiple myeloma. The MajesTEC-9 study enrolled patients with ...